Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.
- Trial name
- NCT00640510
- Testing
- Rapid Acting Intramuscular Olanzapine, Isotonic sodium chloride solution
- Where
- 11 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.
- Trial name
- NCT00177580
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Schizophrenia
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to…
- Trial name
- CANGLIA (NCT02932605)
- Testing
- Cannabidiol
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- UMC Utrecht
Schizophrenia
Effect of Psychoeducation -Based Motivational Interviewing on Knowledge and Hope in Schizophrenia
This study aimed to examine the effect of a psychoeducation-based motivational interviewing intervention on schizophrenia-related knowledge and hope levels among patients diagnosed with schizophrenia.
- Trial name
- NCT07365982
- Testing
- Psychoeducation-Based Motivational Interviewing
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Büşra Taşkıner
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Schizophrenia
Efficacy of ISST in Schizophrenia
The ISST study investigates whether integrated social cognitive remediation and social behavioral skills therapy is more efficacious in improving functional outcome and treatment adherence than an active control treatment…
- Trial name
- NCT02678858
- Testing
- Integrated Social Cognitive and Behavioral Skills Therapy, Neurocognitive Remediation Therapy
- Where
- 6 sites in Germany
- Volunteers
- 177 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Schizotypal and Delusional Disorders
The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia
This study investigates the effects of using a smartphone app to support shared decision making (SDM) for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
- Trial name
- NCT03554655
- Testing
- Momentum app
- Where
- 7 sites in Denmark
- Volunteers
- 194 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia; Negative Type, Transcranial Alternating Current Stimulation
Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia. Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks.
- Trial name
- NCT06888726
- Testing
- High-intensity transcranial alternating current stimulation (Hi-tACS)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizo Affective Disorder
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.
- Trial name
- CATOS (NCT03794076)
- Testing
- Cromoglycate
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia, Schizoaffective Disorder
Biomarker Study of Acamprosate in Schizophrenia
NMDA receptors are brain receptors that are stimulated by glutamate. Poorly functioning NMDA receptors are thought to be involved in the pathology of schizophrenia.
- Trial name
- NCT00688324
- Testing
- Acamprosate
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Maryland, Baltimore
Schizophenia Disorder, Major Depression Disorders
Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
The goal of this clinical trial is to find if patients would awaken quickly after electroconvulsive treatment when remimazolam is used compared to etomidate. It will also learn about the efficacy of remimazolam.
- Conditions
- Schizophenia Disorder, Major Depression Disorders, Schizoaffective Disorder, Bipolar
- Trial name
- NCT06664138
- Testing
- Remimazolam, Etomidate
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yeongseok Yun
Psychosis
Cognitive Behavioural Therapy-Informed Groups for Psychosis
This is a feasibility study of cognitive behavioural therapy-informed groups for psychiatric inpatients with positive symptoms of psychosis.
- Trial name
- CBTp (NCT05584215)
- Testing
- Cognitive Behavioural Therapy for Psychosis Groups
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Obesity, Schizophrenia
Lifestyle Modification for Weight Loss in Schizophrenia
The purpose of this study is to find out how effective lifestyle modification group therapy is on reducing body weight when compared to usual care in individuals with schizophrenia and/or schizoaffective disorder.
- Conditions
- Obesity, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00990925
- Testing
- Nutritional Lifestyle Modification Group, Usual Care
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Yale University
Relapse in Schizophrenia
Seroquel XR in the Long Term Treatment of Schizophrenia
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
- Trial name
- SereNIS (NCT01202617)
- Where
- 61 sites in Hungary
- Volunteers
- 1,606 people
- Sponsor
- AstraZeneca
Schizophrenia
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
To compare inpatient psychiatric hospitalization rates while participants are on oral standard-of-care antipsychotic treatment and later switched to Abilify MyCite®.
- Trial name
- NCT03892889
- Testing
- Abilify MyCite®
- Where
- 68 sites in United States
- Volunteers
- 277 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia
The purpose of this study is to examine the long-term economic, functional and clinical outcomes in schizophrenia patients who require a change in antipsychotic treatment, and are changed to either paliperidone extended release…
- Trial name
- POST (NCT00488891)
- Testing
- Paliperidone ER, Atypical antipsychotics (AAP)
- Volunteers
- 43 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.